How This Pharma Company Can Benefit From Its Competitors

The race is on among pharmaceutical companies to obtain approval from the U.S. Food and Drug Administration (FDA) for new products serving the atopic dermatitis (AD, otherwise known as severe and chronic eczema) market. One of those companies, Incyte (NASDAQ: INCY), is coming off successful phase 3 trials of its ruxolitinib cream, but is now facing challenges brought on by delays in FDA approval.



from RSSMix.com Mix ID 8260652 https://ift.tt/3cSowj2

Comments

Post a Comment

Popular posts from this blog

Cards replace Yanks as White Sox opponent at Field of Dreams

The St. Louis Cardinals have replaced the New York Yankees as the opponent for the Chicago White Sox in the Field of Dreams game on Aug. 13 at Dyersville, Iowa. The schedule change caused by the new coronavirus pandemic meant the White Sox no longer play the Yankees this season. The new opponent, first reported by The Des Moines Register, was confirmed to The Associated Press by a person familiar with the arrangements who spoke on condition of anonymity Wednesday because the matchup has not been announced. from RSSMix.com Mix ID 8260652 https://ift.tt/3ipcheH
Read more